Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment of severe chronic plaque psoriasis in children.

A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY
A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY

Humira can now be used in children from 4 years old with severe chronic plaque psoriasis who are inappropriate for, or have not responded sufficiently to topical therapies and phototherapies. The recommended dose is based on weight and administered subcutaneously weekly for the first two weeks then every other week. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases